United States: Court Lowers The Bar For Numerosity Requirement In Nexium Antitrust Litigation

Last Updated: December 20 2013
Article by Katherine S. Kayatta

On the heels of his November 4, 2013 order certifying a class of individual consumers and other payors who alleged that defendant pharmaceutical companies engaged in anti-competitive practices resulting in overcharges for the drug Nexium, Judge William G. Young of the District of Massachusetts entered an order on December 11, 2013, this time certifying a class of "Direct Purchaser" wholesalers and retailers who purchased branded Nexium directly from defendant AstraZeneca.  While Judge Young's November 4, 2013 memorandum and order focused primarily on discussion concerning the Rule 23(b)(3) damages class including members lacking any injury from the defendants' alleged practices, the most notable aspect of this most recent order is the Court's discussion of Rule 23(a)'s numerosity requirement. Download In re Nexium Antitrust Litigation Civil Action No 12 md 02409 WGY

Wholesalers, retailers, and consumers brought this putative class action against several defendants for alleged violations of federal antitrust laws involving AstraZeneca's heartburn medication, Nexium.  Wholesaler and retailer plaintiffs sought certification of a class of "Direct Purchasers" who purchased Nexium directly from AstraZeneca and who will purchase generic Nexium directly from one or more of the other "Generic Defendants."  Unlike the defendants' opposition to the previous consumers' motion for class certification, this time the defendants strongly contested whether the Direct Purchaser plaintiffs satisfied Rule 23(a)'s numerosity requirement. 

At the outset, the Court noted the general rule that classes exceeding forty plaintiffs are deemed sufficient for Rule 23(a) purposes.  However, the Court noted that some classes of fewer plaintiffs have previously been certified in the District of Massachusetts.  Specifically, the Court referenced In re Prograf Antitrust Litig., No. 1:11-cv-10344-RWZ, 2013 WL 2395083 (D. Mass. Spr. 23, 2013) (Judge Zobel certified a class of twenty-five pharmaceutical wholesalers) and In re Citigroup, Inc. Capital Accumulation Plan Litig., No. 00cv11912-NG, 2010 WL 9067986 (D. Mass. Jan. 6, 2010) (Judge Gertner certified a subclass of twenty participants in an employee stock compensation program).  In Nexium, the Direct Purchaser plaintiffs and defendants presented conflicting evidence as to the number of putative class members.  Plaintiffs' expert measured the putative class according to two "but-for" generic drug entry dates, April 14, 2008 and January 1, 2012, resulting in either thirty-one or twenty-six class members.  Alternatively, defendants pegged the proper figures at twenty-nine or twenty-four members, which they argued accounted for consolidation of entities with their respective parent companies.  The Court adopted defendants' proposed numbers of twenty-nine or twenty-four.  Despite both ranges falling well below the general forty-member threshold for satisfying numerosity, the Court opined "...it is clear that district courts have taken a more flexible approach to the numerosity analysis."  Nexium, p. 4.  The Court reasoned that the test for numerosity requires courts to address whether joinder of all members is impracticable. 

Explaining that because size of the putative class alone does not establish a "clear case for numerosity," the Court identified several "non-numeric" factors which must be considered in determining whether joinder is impracticable.  They include geographic location of the proposed class members, the nature of the action, and matters of judicial economy.

First, the Court agreed with the Direct Purchasers that, because members of the putative class are geographically dispersed throughout the country, joinder would be difficult, inconvenient, and costly.  Second, the Court recognized that many courts have given favorable treatment to class actions in the private enforcement of antitrust laws, in part because a class action is a fitting mechanism for such enforcement.  Third, the Court concluded that judicial economy would be served through a class action where members seek damages stemming from the same transactions between AstraZeneca and the other generic drug defendants.  The Court determined that plaintiffs had met Rule 23(a)(1)'s numerosity requirement in light of the foregoing analysis of objective and subjective factors.

The Court next reviewed the issue of adequacy.  Defendants disputed whether two assignees of Direct Purchaser claims, both of which were excluded from plaintiffs' expert's report identifying Direct Purchasers, could be included in the proposed class and serve as class representatives.  The Court rejected defendants' arguments. 

The Court then reviewed the requirements of Rule 23(b)(3).  It held that the Direct Purchasers had established that they could prove common damages using a reasonable and acceptable methodology based on sales data and benchmarked against a similar drug, Prevacid, and its generic equivalent.  With regard to superiority, the Court noted that it was a "close call" as to whether the requirement had been satisfied.  Defendants  made "powerful" arguments that these class members are economically well-suited for individual suits because of their alleged one billion dollars in damages claimed per plaintiff.  However, despite the close call, "the complex nature of this litigation, the fact that complete joinder of the Direct Purchaser class is impracticable, and the 'desirability' of concentrating litigation in this single forum" led the Court to its ultimate conclusion that class treatment is superior to other methods of adjudication.  Accordingly, the Court certified a class of all persons or entities in the United States who purchased branded Nexium directly from AstraZeneca at any time during the relevant period.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.